Login to Your Account



Top-Line Good in Phase III PFS

Ovarian Results Carry 'Wait'; Amgen OS Data Due in 2014

By Randy Osborne
Staff Writer

Thursday, June 13, 2013
Although Amgen Inc.'s top-line data from TRINOVA-1, the first of three Phase III trials evaluating trebananib, also known as AMG 386, proved positive in ovarian cancer with regard to progression-free survival (PFS), whether this will be enough for approval remains in question.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription